Safety and efficacy of the leukocytapheresis procedure in eighty-five patients with rheumatoid arthritis

• Published in: Transfusion and apheresis science 2016-10, Vol.55 (2), p.225-232
• Main Authors: Kitagaichi, Mie, Kusaoi, Makio, Tsukahara, Takayoshi, Murayama, Go, Nemoto, Takuya, Sekiya, Fumio, Kon, Takayuki, Ogasawara, Michihiro, Kempe, Kazuo, Yamaji, Ken, Tamura, Naoto, Tsuda, Hiroshi, Takasaki, Yoshinari
• Format: Article
• Language: English
• Subjects: Antirheumatic agents; Antirheumatic Agents - administration & dosage; Arthritis, Rheumatoid - blood; Arthritis, Rheumatoid - pathology; Arthritis, Rheumatoid - physiopathology; Arthritis, Rheumatoid - therapy; C-Reactive Protein - metabolism; Health technology assessment; Hematology, Oncology and Palliative Medicine; Humans; Inflammatory bowel diseases; Leukapheresis - methods; Leukocytapheresis; Male; Methotrexate; Middle Aged; Rheumatoid arthritis
• ISSN: 1473-0502; 1878-1683
• DOI: 10.1016/j.transci.2016.07.019

Abstract Rheumatoid arthritis (RA) is a systemic inflammatory disease in which the predominant symptom is polyarthritis that follows a chronic and progressive clinical course characterized by destructive synovitis and various immune disorders. Striking progress in RA treatment was achieved with the emergence of monoclonal antibodies to target cytokines. However, drug choices are limited for many patients due to resistance to multidrug antirheumatic therapy, concomitant disease, and infection. We evaluated the efficacy of treatment in 85 patients with RA for whom leukocytapheresis (LCAP) was initiated at our hospital between 2006 and 2015. All patients continued drug therapy and were treated with LCAP once a week for up to 5 weeks. The clinical response was evaluated at the completion of LCAP series and 4 weeks later using the American College of Rheumatology (ACR) criteria and the 28-joint disease activity score (DAS28) of European League Against Rheumatism (EULAR). The tender joint counts, swollen joint counts, and C-reactive protein (CRP) levels decreased remarkably. DAS28-CRP was significantly improved by LCAP. And furthermore, the efficacy lasted at least 4 weeks after the completion of LCAP. These results suggest that LCAP is a beneficial and are consistent with several trials' reported effect of LCAP. This treatment can contribute to improvements in activities of daily living (ADLs) and long-term outcome by improving swollen and tender joint counts and CRP levels even in refractory patients for whom the use of conventional disease-modifying antirheumatic drugs (DMARDs) and biopharmaceuticals is problematic. LCAP might be a promise therapy to refractory RA.